Abstract:Numerous peptides inhibit the entry of enveloped viruses into cells. Some of these peptides have been shown to inhibit multiple unrelated viruses. We have suggested that such broad-spectrum antiviral peptides share a property called interfacial activity; they are somewhat hydrophobic and amphipathic, with a propensity to interact with the interfacial zones of lipid bilayer membranes. In this study, we further tested the hypothesis that such interfacial activity is a correlate of broad-spectrum antiviral activity. In this study, several families of peptides, selected for the ability to partition into and disrupt membrane integrity but with no known antiviral activity, were tested for the ability to inhibit multiple diverse enveloped viruses. These include Lassa pseudovirus, influenza virus, dengue virus type 2, herpes simplex virus 1, and nonenveloped human adenovirus 5. Various families of interfacially active peptides caused potent inhibition of all enveloped viruses tested at low and submicromolar concentrations, well below the range in which they are toxic to mammalian cells. These membrane-active peptides block uptake and fusion with the host cell by rapidly and directly interacting with virions, destabilizing the viral envelope, and driving virus aggregation and/or intervirion envelope fusion. We speculate that the molecular characteristics shared by these peptides can be exploited to enable the design, optimization, or molecular evolution of novel broad-spectrum antiviral therapeutics.IMPORTANCE New classes of antiviral drugs are needed to treat the ever-changing viral disease landscape. Current antiviral drugs treat only a small number of viral diseases, leaving many patients with established or emerging infections to be treated solely with supportive care. Recent antiviral peptide research has produced numerous membrane-interacting peptides that inhibit diverse enveloped viruses in vitro and in vivo Peptide therapeutics are becoming more common, with over 60 FDA-approved peptides for clinical use. Included in this class of therapeutics is enfuvirtide, a 36-residue peptide drug that inhibits HIV entry/fusion. Due to their broad-spectrum mechanism of action and enormous potential sequence diversity, peptides that inhibit virus entry could potentially fulfill the need for new antiviral therapeutics; however, a better understanding of their mechanism is needed for the optimization or evolution of sequence design to combat the wide landscape of viral disease.

Antiviral Protein-Protein Interaction Inhibitors

Protein- and Peptide-Based Virus Inactivators: Inactivating Viruses Before Their Entry Into Cells

Current Progress in Antiviral Strategies.

Exploring Viral–Host Protein Interactions as Antiviral Therapies: A Computational Perspective

Recent Advances on Targeting Proteases for Antiviral Development

Antiviral agents targeted to interact with viral capsid proteins and a possible application to human immunodeficiency virus.

Antivirals with common targets against highly pathogenic viruses

Systematic Optimization of Host-Directed Therapeutic Targets and Preclinical Validation of Repositioned Antiviral Drugs

Virus-host interaction networks as new antiviral drug targets for IAV and SARS-CoV-2

Broad‐Spectrum Antiviral Peptides and Polymers

Computer-Aided Prediction of the Interactions of Viral Proteases with Antiviral Drugs: Antiviral Potential of Broad-Spectrum Drugs

A Route to Novel Antiviral Agents and New Therapeutic Approaches

Antiviral biomaterials

Anti-virus reagents targeting the capsid protein assembly

The urgent need for pan-antiviral agents: from multitarget discovery to multiscale design

Virus Entry Inhibitors: Past, Present, and Future

Broad-Spectrum Antiviral Entry Inhibition by Interfacially Active Peptides

A Combined Computational and Experimental Approach

Generation of host-directed and virus-specific antivirals using targeted protein degradation promoted by small molecules and viral RNA mimics

Antiviral Agents against Flavivirus Protease: Prospect and Future Direction

Novel Broad-Spectrum Antiviral Inhibitors Targeting Host Factors Essential for Replication of Pathogenic RNA Viruses